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doi:10.1016/j.jtcvs.2005.10.050ackground: Worsening of lung failure in patients awaiting a lung transplantation
ight lead to ventilation-refractory hypercapnia and respiratory acidosis. Most
ransplant centers consider pretransplantation extracorporeal membrane oxygen-
tion as a contraindication for lung transplantation because of the poor outcome. We
ave, for the first time, applied the novel pumpless interventional lung assist
ovaLung for bridge to lung transplantation in patients with severe ventilation-
efractory hypercapnia. We report on our initial experience.
ethods: Between March 2003 and March 2005, 176 lung transplantations were
erformed, of which 60% were high-urgency lung transplantations. Twelve of the
igh-urgency recipients had severe ventilation-refractory hypercapnia and respira-
ory acidosis. These patients were connected to the novel pumpless interventional
ung assist NovaLung for bridge to lung transplantation.
esults: The length of interventional lung assist NovaLung support was 15 8 days
4-32 days). PaO2, pH, and PaCO2 levels in arterial blood prior to interventional lung
ssist NovaLung implantation were 71  27 mm Hg, 7.121  0.1, and 128  42
m Hg, respectively. Six hours after interventional lung assist NovaLung implan-
ation, PaO2, pH, and PaCO2 levels had changed to 83  17 mm Hg (ns), 7.344 
.1 (P  .05), and 52  5 mm Hg (P  .05), respectively. Four patients died of
ultiorgan failure, 2 patients before and 2 after lung transplantation. Thus, 10 out
f 12 patients were successfully bridged to lung transplantation, and 8 are still alive
1-year survival, 80%).
onclusions: This report suggests that interventional lung assist NovaLung implan-
ation is an effective bridge to lung transplantation strategy in patients with
entilation-refractory hypercapnia.
ung transplantation (LTx) has become a standard treatment modality for
patients with end-stage lung failure, and the worldwide number of proce-
dures annually performed is continuously expanding.1 However, the number
f patients listed for LTx is also increasing and reaches far beyond the amount of
vailable donor organs. As a consequence, the waiting list mortality is still relevant
nd, dependent on the underlying disease, might reach 20% during the first year and
p to 40% after 2 years of listing.2 These data clearly indicate that the current
aiting times are too long for a relevant number of patients awaiting an LTx.
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TXIn the EuroTransplant environment, patients who are
isted for LTx might be listed for high-urgency (HU) LTx if
hey fulfill defined criteria of progressing end-stage lung
ailure. According to the guidelines, these patients have to
e hospitalized in the transplant center and often require
oninvasive or even invasive ventilatory support. Evidence
xists that mechanical ventilation before LTx is a significant
isk factor for mortality after LTx3 and certainly needs to be
voided. It carries a high risk of infection, muscle fatigue,
entilation-associated lung injury, and, ultimately, remote
rgan dysfunction, as previously shown by the Toronto
roup.4 Currently, patients have to wait up to several
onths for an HU LTx in the EuroTransplant region. As a
onsequence, approximately 25% of the HU patients at The
annover Thoracic Transplant Program require mechanical
entilation before LTx.5 Some of these patients, however,
ight have further life-threatening ventilation-refractory
ypercapnia and respiratory acidosis, despite maximal ven-
ilatory support. The only treatment option for these patients
s extracorporeal gas exchange. Until now, extracorporeal
embrane oxygenation (ECMO) has been the only techni-
al option, but it can be applied for a very limited period of
ime only and has side effects, such as hemolysis (80%),
nfection (20%-25%), renal insufficiency (30%-40%), and
leeding complications (50%-60%). Moreover, the outcome
f LTx after pre-LTx ECMO implantation is poor, with a
erioperative mortality of up to 60%.6
The interventional lung assist NovaLung (iLA; NovaLung
mbH, Hechingen, Germany) is a low-resistance lung assist
evice designed for pulsatile blood flow with tight diffusion
embranes and a protein matrix coating.7 It is driven by the
ardiac output and therefore does not require extracorporeal
ump assistance. In the clinical setting the iLA has been
pplied in a variety of clinical situations, such as severe
hest trauma, pneumonia, adult respiratory distress syn-
rome, and airway obstruction. Furthermore, it has been
elpful in the weaning process from mechanical ventilation
n a single case.7 However, the role of iLA in LTx has not
een investigated yet. Here we report on our initial experi-
nce with the iLA as a bridge to LTx in patients with
nd-stage pulmonary failure.
ethods
etween March 2003 and March 2005, 176 LTx procedures were
Abbreviations and Acronyms
AVCO2R  arteriovenous CO2 removal
ECMO  extracorporeal membrane oxygenation
HU  high urgency
iLA  interventional lung assist NovaLung
LTx  lung transplantationerformed at the Hannover Thoracic Transplant Program, of which g
20 The Journal of Thoracic and Cardiovascular Surgery ● Marc0% were HU LTxs for patients who fulfilled the HU criteria
ostulated by the European Donor Allocation Foundation
uroTransplant.
The iLA was CE certified in Europe in 2003 as an extracorpo-
eal gas exchange device to allow protective mechanical ventila-
ion and as a rescue device in patients with ventilation-refractory
ung failure. This study was a prospective observational study
pproved by the ethics committee of the Hannover Medical
chool. All patients were sedated and ventilated at maximum
evels at the time of the decision for device implantation, and
herefore patients’ advocates consented to participate in the
tudy.
Twelve of the HU recipients had severe ventilation-refractory
ypercapnia and respiratory acidosis and were screened for iLA
mplantation. After exclusion of all potential contraindications for
LA, which include low cardiac output, cardiogenic shock, and
dvanced peripheral atherosclerosis,8 venoarterial cannulation for
evice connection in a femorofemoral position was performed. In
ll patients arterial blood samples were taken for blood gas anal-
sis immediately before iLA implantation. Further arterial blood
as samples were taken 6, 24, and 72 hours and 7 days after iLA
mplantation. Because of clinical constraints, the available values
losest to the previously listed time points were used for the
nalysis. In addition, systemic arterial blood pressure, peak venti-
atory pressure, fraction of inspired oxygen, and positive end-
xpiratory pressure were prospectively recorded and retrospec-
ively analyzed, and the PaO2/fraction of inspired oxygen ratio was
alculated.
mplantation Technique
efore iLA implantation, all patients received an intravenous
ingle dose of heparin of 10,000 IU. Implantation of the cannulas
as performed under sterile conditions in the intensive care unit.
n arteriovenous shunt was instituted by using 2 low-resistance
annulas. First, the left femoral artery was punctured, and a guide
ire was introduced (Seldinger’s technique). The puncture hole
as then dilated to the diameter of the cannula (15F) with a dilator
it provided by the manufacturer. The cannula was introduced into
he artery and clamped. Next the right femoral vein was also
unctured transcutaneously, and a wire was introduced, which
uided a 17F cannula into the femoral vein. The lung assist device
nd the short tubing system were completely deaired with normal
aline solution by a perfusionist. Finally, the tubes were connected
o the cannulas, and the clamps were removed. Immediately, blood
ows through the arterial line into the device and returns through
he venous cannula. A gas tube that provides the oxygen is con-
ected to the device. A flow probe can be connected to the tubing
ine to monitor the circulating blood volume through the device.
ll patients received continuous intravenous heparin administra-
ion according to the activated clotting time, which was kept at 160
o 180 seconds and measured in 4-hour intervals. Accidental
lotting of the membrane can be detected by continuous iLA blood
ow monitoring. However, if this probe is not available, blood gas
nalyses from the venous line can also indicate malfunction of the
LA. In our patients proper function of the device was tested by
sing repeated blood gas analyses from the venous line in
-hour intervals. We tried to keep mean arterial blood pressure
reater than 80 mm Hg to achieve adequate blood flow through
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TXhe iLA. If necessary, patients received continuous low-dose
orepinephrine administration. Figure 1 depicts the interven-
ional lung assist after femoral arteriovenous insertion. It is
oteworthy that the device is placed in a stabile position be-
ween the patient’s legs for proper function. In all patients the
lood supply to the lower extremities was frequently checked
y the physician in charge using clinical examination or Dopp-
er ultrasonography.
tatistical Analysis
here the assumptions of homogeneity and normality were met,
he t test was used. Where these assumptions were not met, the
ann-Whitney U test was used. The SigmaStat version 1.0 (Jandel
cientific, San Rafael, Calif) software package was used for all
tatistical analyses.
esults
ll patients were mechanically ventilated and sedated. The
ndication for iLA implantation was ventilation-refractory
ypercapnia with accompanying severe respiratory acidosis.
igure 1. Femoral connection of the interventional lung assist
evice (iLA) in the clinical setting.
ABLE 1. Changes in blood gases, hemodynamics, and the
Before iLA
BL (n  12) 6  0 h (n  12)
AP (mm Hg) 72 8 74  7
aO2 (mm Hg) 71  27 83  17
aCO2 (mm Hg) 128 42 52 5
H 7.121 0.1 7.344 0.1
O2/FIO2 ratio 135 33 150 24
eak VP (mm Hg) 45 5 45  5
EEP (mm Hg) 13 1 13  1
LA, Interventional lung assist device; BL, baseline before interventional lun
f inspired oxygen; VP, ventilatory pressure; PEEP, positive end-expiratory pres
The Journal of Thoraciche underlying diseases were bronchiolitis obliterans in 3
atients who were listed for redo LTx, idiopathic pulmonary
brosis in 4 patients, cystic fibrosis in 2 patients, emphy-
ema in 1 patient, inhalation trauma in 1 patient, and lym-
hangioleiomyomatosis in another patient. The mean dura-
ion of iLA support in the 12 patients was 15 8 days (4-32
ays). Arterial blood gas analyses before iLA implantation
evealed PaO2, pH, and PaCO2 values of 71  27 mm Hg,
.121  0.1, and 128  42 mm Hg, respectively. Six hours
fter iLA implantation, however, PaO2, pH, and PaCO2 val-
es had changed to 83 17 mm Hg, 7.344 0.1 (P .05),
nd 52  5 mm Hg (P  .05), respectively. Table 1
ummarizes changes in arterial blood gases and the arterial
H over time and also changes to the ventilatory regimen.
hree patients required replacement of the device for acci-
ental clotting at activated clotting times of less than 150
econds. In these patients only the membrane required re-
lacement, and the in situ cannulas were left in place. Four
atients died of multiorgan failure, 2 before LTx and 2 on
ays 16 and 30 after LTx. Thus, 10 of the 12 patients were
uccessfully bridged to LTx, and 8 are still alive, resulting
n a posttransplantation 1-year survival of 80%. None of the
atients showed signs of malperfusion of the lower extrem-
ties. Seven of the 12 patients with iLAs had systemic
nfection or sepsis, as evident by positive blood cultures.
raditionally, such infections would be viewed as contrain-
ications to conventional ECMO in our institution.
iscussion
e report a novel experience with the pumpless iLA as
ridge to LTx in patients with ventilation-refractory severe
ypercapnia and respiratory acidosis while awaiting trans-
lantation. These patients require extracorporeal gas ex-
hange and, until now, ECMO was the only available treat-
ent option. In 1991, we reported on the use of ECMO for
ridge to redo LTx in patients with severe initial graft
ailure, thereby addressing the abundance of severe compli-
ations with ECMO in lung transplant recipients.9 Many
Tx programs consider mechanical ventilation or the need
tilatory regimen
After iLA implantation
4  5 h (n  12) 72  6 h (n  10) 7  0.5 d (n  7)
78  8 77 6 75 5
124 42 113 28 114 36
51  33 48 8 46 5
7.378  0.2 7.368 0.1 7.392  0.1
168 42 145 24 139 22
32  3 30 5 28  6
6  1 5  2 6  1
ist device implantation; MAP, mean arterial blood pressure; FIO , fractionven
2
g ass 2
sure.
and Cardiovascular Surgery ● Volume 131, Number 3 721
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7
TXor ECMO as a contraindication for LTx because the out-
ome after LTx under these circumstances has been poor.
he widely known side effects of ECMO, such as hemoly-
is, bleeding complications, severe infection, and renal in-
ufficiency, certainly contribute to this poor outcome. More-
ver, ECMO can only be applied reasonably for several
ays. Beyond that, the number of accompanying complica-
ions increases significantly.
The iLA is a low-gradient device designed to operate
ithout the help of an external pump. On the basis of this
rinciple, adequate mean arterial blood pressure is manda-
ory. This device is attached to the systemic circulation and
eceives only part of the cardiac output for extracorporeal
as exchange. This allows complete CO2 removal, which
an be controlled by varying sweep gas flow. Oxygenation,
owever, depends on shunt, arterial oxygenation saturation,
nd other variables. The native lung in this situation also
ontributes. The limited increase in oxygenation, as seen in
he early postimplantation period in our patients, might
otentially be life saving in some patients with oxygenation
eficiency. However, patients with a primary oxygenation
isorder might not necessarily benefit from iLA.7 Important
echnical details of the iLA are depicted in Table 2.
The concept of interventional lung assistance was men-
ioned by Rashkind and colleagues in 1967.10 Various clin-
cal and experimental modifications and studies were per-
ormed until the first commercially available pumpless lung
ssist device, which is the NovaLung, had been developed
Figure 1). In 1999, Zwischenberger and associates11 re-
orted on a series of 5 patients who were approved for
reatment of severe respiratory failure and CO2 retention to
valuate the feasibility and safety of percutaneous arterio-
enous CO2 removal (AVCO2R). In that initial clinical
tudy with a pumpless low-resistance oxygenator (Affinity;
vecor Cardiovascular, Plymouth, Minn), approximately
0% CO2 removal in adults with severe respiratory failure
nd CO2 retention was achieved without hemodynamic
ompromise or instability according to mean arterial blood
ressure measurements. This is consistent with our findings
ABLE 2. Technical data of the interventional lung assist
ovaLung
embrane Polymethyl pentene diffusion
urface area 1.3 m2
lood flow 0.5-4.5 L/min
aximum gas flow 15 L/min
illing volume 240 mL
ressure decrease 11 mm Hg at 2.5 L/min
max 200 mm Hg
oating Protein matrix  heparin
illing Connect to normal saline for 3 minutes
esigned for pulsatile blood flow. Pmax, Maximum pressure.ith the Novalung. The hemodynamic stability while con- a
22 The Journal of Thoracic and Cardiovascular Surgery ● Marcected to an AVCO2R device has also previously been
eported in adult sheep by the same group of research-
rs.12,13 In another study by this group, ventilation pressures
ould be significantly reduced in a sheep model of severe
ulmonary injury caused by smoke inhalation after connec-
ion of the animal to a low-resistance AVCO2R device.14
his is also consistent with our findings in this clinical study
sing the low-resistance iLA.
The Novalung has been applied in approximately 500
ases worldwide, including trauma, lung infection, adult
espiratory distress syndrome, airway obstruction, and oth-
rs, as reported by Matheis.7 In the majority of cases re-
orted, the iLA was an adjunct to mechanical ventilation
hat allowed use of optimized lung-protective ventilation
trategies, with the objective of giving the lung time to heal
hile attempting to minimize ventilation-induced lung in-
ury. Moreover, in single cases the iLA was used without
echanical ventilation in the awake and nonsedated pa-
ient.7 This is the first report on the application of the iLA
s a bridge to LTx. Patients with end-stage lung failure in
hom maximal conventional ventilatory support fails are a
ery high-risk population. Nevertheless, 10 of 12 patients
ere successfully bridged to LTx, of whom 8 are still alive.
he 2 patients who died before LTx died of severe infection.
he other 2 patients, who died after LTx, had remote organ
ailure before transplantation and died of multiorgan failure
fter LTx. In these cases it is possible that iLA implantation
hould have been performed at an earlier point in time. On
he basis of these promising results, we have changed our
pproach toward earlier implantation of this lung assist
evice in mechanically ventilated patients who require
dvanced ventilatory support. This strategy provides the
nique ability to separate ventilation from oxygenation and
herefore likely will help to prevent additional ventilation-
ssociated lung injury, which is becoming increasingly rec-
gnized as a contributor to remote organ failure.4
We acknowledge the following limitations of this study.
e decided to assess device function by blood gas analysis
n samples taken from the venous outflow cannula. There-
ore, we have not measured device flow. Another parameter
hat would reflect the efficiency and efficacy of the iLA
etter would be the PO2 and PCO2 calculated from the
orresponding gas pressures in the arterial inflow and the
enous outflow cannulas. We have also not assessed hemo-
ynamic changes in the pulmonary vasculature or the car-
iac output, but we underscore that these measures are
ffected by a variety of other confounding synchronous
actors, such as nitric oxide inhalation, prostaglandin neb-
lization, PaCO2 levels, catecholamine support, ventilatory
etup, primary lung disease, and others. Furthermore, the
umber of patients in this study is small.
In conclusion, our initial experience demonstrates the
pplicability of the iLA as a bridge to LTx in patients with
h 2006
ed
e
o
t
u
F
r
c
l
r
t
c
f
t
l
h
b
R
1
1
1
1
1
Fischer et al Cardiothoracic Transplantationnd-stage lung failure. There are unique strategies to this
evice, such as its pumpless character and its ability to
ffectively remove CO2. Thereby it normalized the pH in
ur patients. The interventional lung assist is our favored
reatment for patients with ventilation-refractory lung fail-
re with predominant hypercapnia and respiratory acidosis.
uture studies should investigate further some of the theo-
etic potential advantages of iLA, such as whether the iLA
an be used to reduce intracranial pressure by keeping CO2
evels low or to prevent ventilation-induced lung injury and
emote organ failure. We are currently examining the role of
he iLA in the management of posttransplantation compli-
ations, such as severe acute rejection and acute graft
ailure.
Likely the spectrum of indications for the application of
he iLA will increase as we further study the capabilities and
imitations of this device.
We acknowledge the invaluable help of Ms Petra Oppelt, who
as reviewed statistical data analysis in this study as a professional
iostatistician.
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